喜树碱
光动力疗法
伊立替康
结合
拓扑替康
光敏剂
化疗
体内
化学
组合化学
药理学
癌症研究
姜黄素
医学
癌症
生物
生物化学
内科学
光化学
结直肠癌
有机化学
生物技术
数学分析
数学
作者
Yiping Guo,Hongmei Liu,Haijun Xiao,Minghao Yuan,Yushi Liu,Vladimír Sedlařík,Wei‐Chun Chin,Juanru Liu,Li Guo,Changqing Li
标识
DOI:10.1016/j.jphotobiol.2021.112124
摘要
Camptothecin (CPT), an alkaloid, was first discovered from plants and has potent anti-tumor activity. Since then, CPT analogs (namely Irinotecan and Topotecan) have been approved by the FDA for cancer treatments. Curcumin, on the other hand, is a widely used photosensitizer in photodynamic therapy (PDT) treatment. In our previous work, we have reported a straightforward strategy to construct a drug self-delivery system in which two-molecular species Irinotecan and Curcumin can self-assembly into a complex of ion pairs, namely ICN, through intermolecular non-covalent interactions. We found that ICN has slightly better chemotherapy efficacy than its individual components with much fewer side effects. In this paper, we aim to combine the chemotherapy and the PDT of ICN to further improve its anti-tumor performance. The efficient cellular uptake of ICNs was observed by confocal microscopy. Dichloro-dihydro-fluorescein diacetate (DCFH-DA) assay was used to detect the generation of singlet oxygen species. We found that the cell viability was 9% with both chemotherapy and PDT, and 31% with chemotherapy alone for the case with an ICN concentration of 10 μM, which demonstrated that the anti-tumor efficacy against the HT-29 cancer cell line was enhanced substantially with the combination therapy strategy. The study with an in vivo mouse model has further verified that the chemo-PDT dual therapy can inhibit tumor growth by 84% and 18.8% comparing with the control group and the chemotherapy group, respectively. Our results demonstrated that the new strategy using self-assembly and carrier-free nanoparticles with their chemo-PDT dual therapy may provide new opportunities to develop future combinatorial therapy methods in treating cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI